Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 124-128

  Lass Florl C ^a   Nagl, M ^a   Speth, C ^a   Ulmer, H ^a   Dierich, M P ^a   Wurzner R ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; DYE; DYE FUN 1; ITRACONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ASPERGILLUS TERREUS; CELL VIABILITY; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; FUNGICIDAL ACTIVITY; FUNGUS HYPHAE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRAIN DIFFERENCE;

ANTIFUNGAL AGENTS; ASPERGILLUS; COLORING AGENTS; DYE DILUTION TECHNIQUE; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

EID: 0035169179     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.124-128.2001     Document Type: Article

References (25)

1. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients
2. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction of acute myeloblast leukaemia
3. Fluorescent probes for wall porosity and membrane integrity in filamentous fungi
4. MMM1 encodes a mitochondrial outer membrane protein essential for establishing and maintaining the structure of yeast mitochondria
5. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host
6. Invasive aspergillosis
7. Pulmonary aspergillosis in the acquired immunodeficiency syndrome
8. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
9. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi
10. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
11. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia
12. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi
13. Disseminated Aspergillus terreus infection in immunocompromised hosts
14. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents
15. Comparison of voriconazole and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
16. Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts
17. Activity of voriconazole against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis
18. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B
19. Impact of previous aspergillosis on the outcome of bone marrow transplantation
20. A prospective study of infectious diseases following bone marrow transplantation: Emergence of Aspergillus and cytomegalovirus as the major causes of mortality
21. Antifungal therapy in bone marrow failure
22. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia
23. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts
24. Nosocomial fungal infections: A classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation
25. Rapid susceptibility testing of fungi by flow cytometry using vital staining